| High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. | lymphoma, |
| High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. | lymphoma,testicular, |
| Oncogenic MYD88 mutation is associated with primary diffuse large B-cell lymphomas of central nervous system. | lymphoma, |
| Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. | lymphoma, |
| Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. | lymphoma, |
| Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. | lymphoma, |
| MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. | lymphoma, |
| MYD88 L265P may be an early oncogenic event in Waldenstrom macroglobulinemia pathogenesis. | None |
| A summary of recent progress on elucidating the molecular and cellular processes affected by the oncogenic L265P mutation of MYD88 (review) . | None |